Examen

ACRP CP FINAL EXAM LATEST 2024 REAL EXAM 150 QUESTIONS AND CORRECT ANSWERS|AGRADE

0 fois vendu

Cours
ACRP CP

Établissement
ACRP CP

[Montrer plus]

Aperçu 2 sur 7 pages

Voir l'exemple

Publié le 2 novembre 2024
Nombre de pages 7
Écrit en 2024/2025
Type Examen
Contient Questions et réponses

acrp cp final exam latest real exam
exam questions and correct answersagrade

Établissement ACRP CP
Cours ACRP CP

kartelodoc Membre depuis 6 mois 16 documents vendus

$7.99

Ajouter au panier

Enregistrer

Garantie de satisfaction à 100%
Disponible immédiatement après paiement
En ligne et en PDF
Tu n'es attaché à rien

ACRP CP FINAL EXAM LATEST 2024
REAL EXAM 150 QUESTIONS AND
CORRECT ANSWERS|AGRADE
Crossover - Answer-when each subject is randomized to a sequence of two or more
treatments and hence acts as their own control for treatment comparisons

/.Parallel - Answer-when subjects are randomized to 1 of 2 or more arms, each arm
being allocated a different treatment. Each treatment will include their investigational
product at one or more doses, and one or more control treatments, such as placebo
and/or an active comparator

/.A sponsor is developing an IP for treatment of a medical condition where there is one
additional marketed product approved for treatment of the condition. The sponsor
believes their product works as well or better than the current treatment with fewer side
effects. What is the most-likely study design they will use to test the efficacy of the IP? -
Answer-Non-Inferiority

/.What type of clinical trial most likely requires enrollment of the largest number of
research subjects? - Answer-Therapeutic confirmatory (aka Pivotal Trial, Ph III, or
Comparative Efficacy)

/.Minimum number of membors on an IRB/IEC - Answer-5 .. lay people and medical
professionals can be part of the IRB/IEC

/.Who is responsible for providing the protocol - Answer-The Sponsor

/.The purpose of the SIV is to - Answer--review standard procedures
-review the protocol
-review the blank eCRFs

/.Minimum SAE reporting requirements - Answer-- Subject details (ID not name)
- IP
- Interventions for the event that is being reported
- Details of the event
- Details on the reporter of the event
- Admin and sponsor or company details/

/.Vulnerable subjects - Answer-- Junior members of the medical profession
- Employees of a pharmaceutical company
- Military personnel
- Pregnant Women
- Prisoners

, /.IRB/IEC Evaluates - Answer-- The rights, safety, and well-being of the subjects
participating in the trial
- The subject selection procedure
- The scientific tenability of the trial

/.Serious Adverse Event (SAE) - Answer-- results in death, is life threatening, requires
inpatient admission, prolonged admission, congenital anomaly, or persistent incapacity
-death itself is not neccessarily an sae
- Seriousness does not equal severity in that Serious requires reporting while severe
may not.. Severe may just be used to describe an AE
- Must be reported by sponsor to authorities within 15 calendars days from sponsors
first knowledge of the event

/.Adverse Drug Reaction (ADR) - Answer-- All noxious and unintended response that is
related to any dose
- If the reaction is possibly, probably, or definitely related to the drug, it is considered an
ADR
- All ADRs must be documented
- ADRs are not always AEs

/.Unexpected Event - Answer-Not observed before. Or the
Event occurred more often than previously observed

/.Adverse Event (AE) - Answer-- Any untoward medical occurrence that does not
necessarily have a causal relationship with treatment.
- Can be mild moderate or severe
- Worsening of a pre-existing medical condition is an AE

/.Non-Clinical Study - Answer-- Not conducted on human subjects.
-Provide preliminary safety and pharmacokinetic data needed to support studies in
human

/.Data Safety and Monitoring Board (DSMB) - Answer-- Assesses the progress of a
clinical trial, the safety data, and the critical efficacy endpoints
- Can recommend that sponsors modify, end, or continue a trial. But cannot recommend
they start a new trial

/.WMA - Answer-World Medical Association

/.Declaration of Helsinki - Answer--Created by WMA in 1964
- Defines the ethical principles for medical research involving human subjects i.e.:
1. Importance of ICF Requirement of ethical review and approval of research before it is
undertaken
2. Acknowledgement and guidance of special protections for vulnerable subjects
3. Recommends trials are registered on public database

Les avantages d'acheter des résumés chez Stuvia:

Qualité garantie par les avis des clients

Les clients de Stuvia ont évalués plus de 700 000 résumés. C'est comme ça que vous savez que vous achetez les meilleurs documents.

L’achat facile et rapide

Vous pouvez payer rapidement avec iDeal, carte de crédit ou Stuvia-crédit pour les résumés. Il n'y a pas d'adhésion nécessaire.

Focus sur l’essentiel

Vos camarades écrivent eux-mêmes les notes d’étude, c’est pourquoi les documents sont toujours fiables et à jour. Cela garantit que vous arrivez rapidement au coeur du matériel.

Foire aux questions

Qu'est-ce que j'obtiens en achetant ce document ?

Vous obtenez un PDF, disponible immédiatement après votre achat. Le document acheté est accessible à tout moment, n'importe où et indéfiniment via votre profil.

Garantie de remboursement : comment ça marche ?

Notre garantie de satisfaction garantit que vous trouverez toujours un document d'étude qui vous convient. Vous remplissez un formulaire et notre équipe du service client s'occupe du reste.

Auprès de qui est-ce que j'achète ce résumé ?

Stuvia est une place de marché. Alors, vous n'achetez donc pas ce document chez nous, mais auprès du vendeur kartelodoc. Stuvia facilite les paiements au vendeur.